司法部在查封记者电话记录时忽视了相关政策:监督报告 Latest News

司法部在查封记者电话记录时忽视了相关政策:监督报告

(SeaPRwire) - 华盛顿——根据一份即将发布的监察长报告,在特朗普政府执政期间,联邦检察官在对媒体泄密进行调查时,搜查记者电话记录的过程中,绕过了司法部的一些规定。而这种积极追捕记者消息来源的做法可能会再次出现。 司法部检察长办公室周二发布的这份报告还发现,一些国会工作人员的记录也被检察官获取,仅仅是因为他们接触了机密信息,尽管这是他们工作职责的一部分。其中,获得记录的人包括总统当选人特朗普提名的联邦调查局局长人选,他当时是众议院情报委员会的工作人员。帕特尔去年在对该部门的诉讼中表示,谷歌通知他,该部门已对他发出传票。 尽管这份报告记述的是几年前司法部的行为,但此事具有新的意义,因为帕特尔已经表达了他“追捕”那些“对美国公民撒谎”的媒体成员的愿望,以及他认为联邦政府应该清除反对特朗普的“阴谋者”。 这些言论增加了这样一种可能性:在新的领导下,司法部——特朗普已挑选佛罗里达州前司法部长担任他的司法部长——可能会撤销一项规定,该规定(除有限例外情况外)禁止检察官在对敏感信息泄露进行调查时秘密查封记者的电话记录。 2021年,总检察长采取的行动是在有关司法部在特朗普政府期间获取《华盛顿邮报》、《美国有线电视新闻网》和《纽约时报》记者记录的披露引发强烈抗议之后做出的,这些记录是关于谁泄露了与调查俄罗斯干涉大选和其他国家安全事务相关的政府机密的调查。 监察长发现,司法部在2020年寻求记者记录时,没有遵守几年后才实施的某些部门规定,包括让新闻媒体审查委员会审查请求。该委员会旨在确保除检察官以外的其他官员,包括该部门公共事务办公室负责人,能够对这种努力进行权衡。 根据报告,当时授权从美国有线电视新闻网、《纽约时报》和《华盛顿邮报》获取记录的总检察长,并没有明确批准使用寻求的不披露协议——这是部门政策所要求的。 司法部还查封了民主党众议员和时任众议员以及通过苹果公司从时任白宫法律顾问唐·麦加恩那里获得的数据,这些数据与俄罗斯调查有关的泄密事件有关。 根据报告,该部门追查了两名国会议员和43名国会工作人员的记录。监察长没有发现证据表明发起这些请求的职业检察官存在“报复性或政治动机”。根据报告,在大多数情况下,这些工作人员仅仅是因为他们作为工作职责的一部分接触机密材料的时间与包含秘密信息的新闻报道发表时间非常接近,才被视为嫌疑人。 加兰德的新政策列出了司法部仍然可以获取记者记录的几种情况,包括如果记者涉嫌为外国势力或恐怖组织工作;如果他们因不相关的活动而受到调查;或者如果他们通过犯罪手段(如非法闯入)获得了信息。 在民主党和共和党领导下,司法部都在努力平衡其保护新闻自由的决心和保护国家安全秘密的决心。 总统的第一任司法部长在对被视为积极侵犯新闻自由的行为(包括秘密查封美联社记者和编辑的电话记录)强烈抗议后,宣布了修订后的泄密调查指南。 而特朗普的第一任司法部长在俄罗斯干涉大选调查期间发生一系列披露事件后,于2017年宣布开展打击泄密行动。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
杰米·福克斯在Netflix喜剧特辑中讲述其健康危机细节
“` Latest News

杰米·福克斯在Netflix喜剧特辑中讲述其健康危机细节 “`

(SeaPRwire) - “我回来了!”杰米·福克斯在他的新喜剧特辑《What Had Happened Was…》开头哭着喊着。 对于一位上次喜剧特辑(2002年的音乐特辑《I Might Need Security》)已经是二十多年前的人来说,这并不是一个新颖的开场白,但从福克斯口中说出,这句话就意味深长了。2023年4月,他在亚特兰大拍摄《重返战场》时因“医疗并发症”住院,成为名人阴谋论谣言的焦点。根据你在过去一年里与谁交谈,原因从差点死亡到实际死亡,再到有人试图让他闭嘴而未遂的袭击,说法不一。在这个特辑中,他首次透露了实际发生的事情:他中风了。 如果有人担心《What Had Happened Was…》将会是一个特洛伊木马式的标题,以整个故事的承诺来诱导我们,然后用其他内容来取代它,那么这个担心立刻就消失了。特辑以他住院期间的新闻报道和阴谋视频片段开始,然后福克斯兴高采烈地走上舞台,宣称:“我很高兴还活着。” “你们不知道这感觉有多好,亚特兰大!”他说。“我当时在与死神搏斗,但我现在站在你们面前。”这个特辑兼具解释、脱口秀和崇拜环节,是福克斯写给亚特兰大这座他认为救了他性命的城市的爱情信。 在2023年的几个月里,围绕福克斯疾病的谜团达到了高潮,网络博客、右翼阴谋论者和流行文化参与者纷纷发表评论。尽管他的女儿科琳在特辑开头介绍了她父亲,说他正在康复,情况也很好。一些人认为他的病情比他们被告知的要严重得多,谣传他处于昏迷状态或遭受了严重的致残影响。另一些人更进一步,声称他实际上已经去世,家人正在向公众隐瞒这一消息。反疫苗活动家抓住这一新闻,声称他的病情是新冠疫苗的副作用。另一个特别耸人听闻、毫无根据的谣言是,福克斯在据称被拍到拍摄(Combs目前面临)后被(P Diddy)下毒,迅速传播开来。 “网上说Puffy试图杀我。绝对不会,我早早就离开了那些派对。有些事情看起来不对劲,这里很滑,”他在常规表演中第一次(但绝对不是最后一次)调侃P Diddy。 在长达一小时的表演中,福克斯坦诚地讲述了他过去一年的人生经历。在此之前,他和家人一直对他的病情细节保密,只透露了一些小细节。2023年7月,福克斯首次打破沉默,在Instagram上告诉他的粉丝们:“我知道很多人都在等待或想听到最新消息,但说实话,我只是不想让你们看到我那样。”他接着说:“我不想让你们看到我身上插着管子,试图弄清楚我能不能挺过去。” 他说他想让人们看到他在舞台上跳舞和大笑,这正是他在《What Had Happened Was…》中所做的。他开始跳舞,并与观众开玩笑,谈论他行动自如的情况,当他详细描述了他面临的严重医疗挑战时,这更有力量。 关于中风,他说:“这是一个谜,我们仍然不知道究竟发生了什么,”他详细描述了他在晕倒前遭受了剧烈头痛。“我不记得20天了,”他说,因为他为观众和自己拼凑着时间线。“他或许能够完全康复,但这将是他人生中最糟糕的一年,”他说医生告诉家人他脑出血很严重。“这就是情况,亚特兰大。你终于听到了完整的故事。” 与互联网上大多数阴谋论一样,真相往往远不如最离奇的理论那么有趣。但不太有趣并不意味着不重要,福克斯庄严地表达了重新学习站立、行走和自己清洁身体时的情感动荡。特辑的很大一部分是对他对上帝信仰的回归之旅,他像一位充满激情的牧师在山上分享一样分享了这一点。他带领大家唱赞美歌,并讲述了他与上帝的争论,关于他是否应该承受这种痛苦,他告诉狂热的观众,上帝通过他的家人和医生帮助他恢复健康。 在一个特别感人的时刻,福克斯带出了他最小的女儿安妮莉丝,他说她通过在医院病房里为他演奏吉他将他从死亡边缘拉了回来。她说她一直都想有机会一起演出,当她演奏她的歌时,福克斯一边抱着她的肩膀,一边哭了起来。 《What Had Happened Was…》与其说是一个喜剧特辑,不如说是一场生命的庆祝。在最搞笑的时刻,例如福克斯讲述他在康复期间与哈莉·贝瑞互动的一段,以及模仿丹泽尔·华盛顿和卡特·威廉姆斯等人的一段,福克斯的喜剧时机如此巧妙,以至于你会忘记他已经二十年没有做过脱口秀了,而他一直在忙于各种各样的工作,从他奥斯卡获奖的演出到——更不用说获得格莱美奖了。 但在很大程度上,特辑的幽默感来自于福克斯处理痛苦的方式,他一定会永远不会贬低或不尊重这种痛苦。“我从未放弃我的幽默感,”他说,当谈到康复时,他不得不吞下自尊。他贯穿整场表演的口号是:“如果我能保持幽默,我就能活下去。” 在特辑最后激动人心的时刻,福克斯大胆地利用关于他最离谱的阴谋——他实际上是一个克隆人,取代了原来的杰米·福克斯——将其变成了对自我的庆祝。“世界上没有足够的克隆液来克隆我,”他对着人群喊道。“我是不可克隆的,”他说,因为他回顾了他从《活色生香》到《雷》等最具代表性的角色。最终以坎耶·韦斯特的《Gold Digger》的狂喜表演告终,这首歌他最初有参与演出,他成功地将其重新定义为终极赞美歌。 福克斯在离开舞台前说的最后一句话是“谢谢”。他感谢了他的家人、医生、护理人员、医院、观众和上帝。他甚至感谢那些在网上散布关于他的谎言的人,但在先前的“去你的”之后。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
GATE Energy赢得斯巴达调试合同 Finance

GATE Energy赢得斯巴达调试合同

(SeaPRwire) - 休斯顿, 2024年12月9日 — GATE Energy欣然宣布,已获得壳牌海运公司(Shell Offshore, Inc.)授予的Sparta半潜式项目调试管理和执行合同。GATE Energy拥有业主工程、施工管理以及交钥匙调试和初始启动等能力,提供完整的项目生命周期支持,确保项目从概念到调试的成功。 Mark Myhre,GATE Energy调试总裁,表示:“我们很荣幸能够通过Sparta项目扩展我们与壳牌的长期合作关系。在过去的几年里,GATE已经根据此模型成功交付了多个项目,包括Vito和Whale项目,充分利用了我们的全球能力。我们很高兴能够在此基础上,安全高效地交付Sparta项目。全电气顶部压缩技术代表了海上作业可持续性发展的一大进步,我们期待确保其成功调试。” Lee Jordan,GATE Energy首席执行官,补充道:“我们位于美国和新加坡的团队期待再次与壳牌合作,成功向全球能源市场交付业界领先的低碳墨西哥湾深水生产。” Sparta的设计与日产10万桶的Vito和Whale设计非常相似。GATE Energy在Vito和Whale的调试中发挥了重要作用,并希望继续与壳牌紧密合作,完成Sparta的调试。 该项目将是壳牌首个采用全电气顶部压缩设备的可复制项目,这将大大减少其自身运营的碳排放。 关于GATE Energy GATE Energy是一家100%员工持股的ESOP公司,为能源行业提供可预测的项目交付服务。他们利用参数预测模型,提供严格的项目控制,并在项目的规划阶段积极消除运营问题,从而安全地设计、建造、调试和启动能源设施和资产,避免成本和进度超支。 更多关于GATE Energy的信息,请访问 联系方式:Karthink Annadorai,首席战略官 来源 GATE Energy本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
沉浸式游戏盒扩展全球业务,宣布与PowerPlay加拿大公司和Nikito法国公司达成特许经营协议
“` Finance

沉浸式游戏盒扩展全球业务,宣布与PowerPlay加拿大公司和Nikito法国公司达成特许经营协议 “`

(SeaPRwire) - 伦敦, 2024年12月9日 — Immersive Gamebox (IGB),全球沉浸式团队游戏体验的领导者,今天宣布与加拿大PowerPlay和法国Nikito签订两项突破性的特许经营协议,标志着IGB进军加拿大和法国市场。这些合作伙伴关系代表着IGB将其独特的互动娱乐品牌扩展到全球的重大里程碑。 进军加拿大市场与PowerPlay合作 PowerPlay,加拿大的顶级娱乐目的地,将在其全国各地的场馆推出IGB体验,从2024年12月9日卡尔加里Southcentre购物中心开始。此次合作将IGB配备触摸屏墙、3D动作追踪和投影映射的先进Gamebox与PowerPlay充满活力的娱乐产品相结合。 PowerPlay Immersive Gamebox 的主要特点: 尖端游戏玩法:配备触摸屏墙、3D动作追踪和投影映射,IGB提供无需VR头显的互动体验。 协作乐趣:2-6名玩家的多人游戏,非常适合家庭、朋友和公司团队建设活动。 独家IP体验:进入由粉丝最喜欢的系列(如《鱿鱼游戏》、《捉鬼敢死队》和《愤怒的小鸟》)启发的世界。 “PowerPlay致力于重新定义娱乐,而与Immersive Gamebox的合作完美契合了我们提供难忘体验的使命,”PowerPlay Canada首席执行官Moe Farhat表示。“我们携手正在为加拿大的休闲和娱乐树立新的标杆。” 与Nikito在法国开拓新局面 在法国,IGB正与Nikito(一家家庭娱乐领域的领导者)合作,在其位于罗尼苏布瓦的10万平方英尺的巴黎场馆推出Gamebox。该中心将于2024年12月14日开业,将提供法语本地化游戏体验,以及Nikito广受欢迎的景点,包括卡丁车、保龄球、激光标签、街机和蹦床公园。 巴黎场馆的主要亮点: 2024年12月14日开业:位于罗尼苏布瓦,这个10万平方英尺的中心将包含四个为当地观众量身定制的Gamebox。 本地化游戏:提供法语游戏,为当地玩家提供无缝体验。 Nikito充满活力的环境:Nikito以其超过15个景点的创新娱乐产品而闻名,例如电动卡丁车和现场表演,为Immersive Gamebox的蓬勃发展提供了完美的场所。 “与Immersive Gamebox合作使我们能够通过尖端技术和互动游戏来增强我们的娱乐产品,这将吸引我们的游客,”Nikito首席执行官兼创始人Hugo Perpere表示。“我们很高兴将这一创新概念引入法国,为我们的客人创造难忘的时刻。” “这些特许经营协议是我们全球扩张的关键时刻,”IGB总裁兼首席运营官Lisa Paton表示。“与PowerPlay Canada和Nikito合作使我们能够将我们的沉浸式游戏体验带给新的受众,同时确保我们的内容适应当地文化和偏好。” 关于Immersive Gamebox Immersive Gamebox (IGB) 通过其先进的团队游戏体验,正在彻底改变沉浸式娱乐的世界。IGB配备了3D动作追踪、投影映射和触摸敏感墙壁的先进Gamebox,提供多人游戏,让玩家可以身临其境地体验游戏。IGB在全球拥有超过30个地点,并继续扩大其沉浸式游戏的组合,与领先的品牌和工作室合作创造难忘的体验。在娱乐方面,Immersive Gamebox独树一帜,超过25,000条来自谷歌和猫途鹰的五星级评论使其跻身全球景点前10%。 有关Immersive Gamebox即将开业的地点和启动日期的更多信息,请访问 来源 Immersive Gamebox本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Exro将参加Benchmark第13届年度Discovery投资者大会
“` Finance

Exro将参加Benchmark第13届年度Discovery投资者大会 “`

(SeaPRwire) - 卡尔加里,艾伯塔省, 2024年12月9日 – Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) (“公司”或“Exro”) 是一家领先的清洁技术公司,为电动汽车提供专有的电机控制和完整的电力推进系统技术,今天宣布其将参加Benchmark公司于2024年12月11日星期三在纽约市举行的第13届年度Discovery一对一投资者会议。 此次会议以一对一会议的形式,将新兴增长型公司和充满活力的公司与机构和个人投资者联系起来。Exro将与投资者和分析师互动,讨论其目前为蓝筹汽车原始设备制造商提供的技术产品,以及预计将在2025年及以后持续带来动力的战略举措。 要安排与Exro的一对一会面,请。 Benchmark公司成立于1988年,总部位于纽约市,是一家专注于机构的、以研究为导向的公司,提供销售交易、投资银行、战略咨询服务和股票研究。 关于Exro Technologies Inc. Exro Technologies Inc.通过战略收购SEA Electric而扩张,是一家领先的清洁技术公司,开发了新一代电力控制电子设备。其创新的解决方案套件,包括Coil Driver、Cell Driver和SEA-Drive®,扩展了电动机和电池的功能,并为原始设备制造商提供了具有无与伦比的性能和效率的综合电力推进解决方案。Exro正在重塑全球能源消耗,通过以更少的投入获得更多成果——以最少的能源获得最大的效果——来加速向循环电动经济的过渡。 更多信息请访问我们的网站要查看我们的公司介绍,请访问 在社交媒体上关注我们 @exrotech。 关于前瞻性陈述的警示声明 本新闻稿包含前瞻性陈述和前瞻性信息(统称为“前瞻性陈述”),其含义符合适用的证券法。除历史事实陈述外,所有陈述均为前瞻性陈述。通常,前瞻性陈述可以使用诸如“计划”、“预期”、“估计”、“打算”、“预期”、“相信”或此类词语的变体,或某些行动、事件或结果“可能”、“可以”、“将会”、“可能”、“将采取”、“发生”或“实现”的陈述来识别。前瞻性陈述涉及风险、不确定性和其他因素,这些因素在公司向加拿大证券监管机构提交的文件中“风险因素”标题下以及其他地方披露,这些因素可能导致实际结果、业绩、前景和机会与这些前瞻性陈述明示或暗示的内容存在重大差异。尽管公司认为,截至本新闻稿发布之日,用于编制这些前瞻性陈述的假设和因素是基于目前可供管理层获得的信息的合理假设,但实际结果和发展情况可能与这些陈述中设想的有所重大差异。因此,提醒读者不要过分依赖这些陈述,这些陈述仅适用于本新闻稿发布之日,并且不能保证这些事件将在披露的时间范围内或根本不会发生。除非适用法律要求,否则公司不承担更新或修改任何前瞻性陈述的意图或义务,无论这是由于新信息、未来事件还是其他原因。 本信息在其全部内容上均受公司向加拿大证券监管机构提交的文件中包含的警示性声明和风险因素披露的限定,包括公司截至2023年12月31日止财政年度的年度信息表,以及截至2023年12月31日止财政年度的财务报表及相关MD&A,这些文件已提交给加拿大某些省份的证券监管机构,并可在查阅。如果这些风险或不确定性中的一个或多个成为现实,或者前瞻性信息的潜在假设被证明是不正确的,则实际结果可能与本文所述的预期、计划、预期、相信、估计或期望的结果存在重大差异。尽管公司已试图识别可能导致实际结果存在重大差异的重要风险、不确定性和因素,但可能还存在其他因素导致结果与预期、估计或预期不符。公司不打算也不承担任何义务来更新这些前瞻性信息,除非适用法律另有规定。 多伦多证券交易所和加拿大投资业监管机构均不对本新闻稿的充分性或准确性承担责任。 来源 Exro Technologies Inc.本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Resolution Therapeutics公司宣布在Keystone研讨会上发表关于纤维化的演讲
“` Finance

Resolution Therapeutics公司宣布在Keystone研讨会上发表关于纤维化的演讲 “`

(SeaPRwire) - 苏格兰爱丁堡 and 伦敦, 2024年12月10日 — Resolution Therapeutics Limited (“Resolution” or “Company”),一家专注于开创炎症和纤维化疾病再生性巨噬细胞疗法 (“RMT”) 的临床阶段生物制药公司,今天宣布其已在2024年12月8日至11日在加拿大惠斯勒,卑诗省举行的基石研讨会纤维化:炎症、驱动因素和治疗性消退中展示了一张海报。 该公司展示了其独特的基于细胞的分析和临床前体内实验的组合数据,这些实验是为了满足启动人体首次试验的监管要求而进行的。EMERALD,一项使用多剂量工程巨噬细胞治疗终末期肝病 (ESLD) 的 1/2 期研究,将是首次使用工程巨噬细胞来潜在逆转纤维化。本海报中提出的临床前策略促使英国和西班牙卫生部门在今年早些时候批准了 RTX001 用于终末期肝病的临床试验申请。EMERALD 目前正在积极招募患者。 海报演示的详细信息: 标题:支持 1/2 期工程促再生巨噬细胞治疗终末期肝病临床试验的临床前方案。 出版号:1044 会议日期和时间:海报会议 #1,12月9日,下午7:30 (GMT-8) 演讲者:Keith Sutton,博士——Resolution Therapeutics 临床前开发主任 编者注 关于 RTX001 RTX001 是一种工程自体巨噬细胞疗法,具有增强的抗纤维化和抗炎作用。该候选产品采用 IL-10-MMP9 mRNA 进行工程改造,以增强巨噬细胞的天然再生特性,从而提高疗效和持久性。RTX001 正在一项名为“EMERALD”的 1/2 期开放标签人体首次研究中进行测试,该研究以临床事件为主要疗效终点,用于治疗终末期肝病。EMERALD 研究目前正在招募患者。 关于 EMERALD EMERALD 是一项人体首次的开放标签 1/2 期干预性研究,评估 RTX001 在最近已从肝性失代偿中恢复的终末期肝病患者中的安全性和疗效。该研究在英国和西班牙进行,并于2024年10月开始招募患者。更多信息,请访问 关于 Resolution Therapeutics Resolution Therapeutics 是一家临床阶段生物制药公司,专注于在炎症和纤维化疾病中开创再生性巨噬细胞疗法。该公司利用其专有平台开发具有促再生特性的巨噬细胞,以获得优异的患者疗效。Resolution 的最初重点是开发其主要产品 RTX001,该产品具有同类首创的潜力,并得到临床前数据支持,这些数据表明其相对于非工程巨噬细胞具有抗纤维化和抗炎优势,用于治疗终末期肝病患者。该公司还在努力将其平台的潜力扩展到肝脏疾病以外的炎症和纤维化适应症,包括移植物抗宿主病 (GVHD) 和肺纤维化。Resolution 是从爱丁堡大学Stuart Forbes 教授的实验室分离出来的,总部位于爱丁堡和伦敦。访问了解更多信息,并在 上与我们互动。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 ```
More
OGeez!推出无糖软糖 Finance

OGeez!推出无糖软糖

(SeaPRwire) - 该公司已在亚利桑那州推出无糖大麻软糖,并计划于2025年初将其引入新泽西州和伊利诺伊州 凤凰城, 2024年12月9日 — OGeez! 为大麻社区带来了一份年末大礼:一款新的无糖软糖。 这款软糖于11月在Trulieve位于亚利桑那州的21家药房独家推出,现在已正式登陆大峡谷州的药房货架。 这款热带风味混合装——包括草莓奇异果、西瓜番石榴和百香果芒果软糖——增加了该公司广受好评的、针对性强的软糖产品系列。 OGeez! 首席执行官Bran Noonan表示,对无糖软糖的需求在“各种消费者”中都很强烈。 他说:“我们一直在努力满足人们的需求。”“但我们的标准很高,我们需要确保我们提供的是一款不会牺牲我们标志性风味和质地的无糖软糖。我很高兴地报告说,我们绝对做到了这一点。消费者和药剂师们已经表示,他们不敢相信里面没有糖。” 无糖软糖的消息紧随该公司在伊利诺伊州和新泽西州两个新州推出的消息之后,预计这两个州今年的大麻销售总额将达到约30亿美元。 此外,OGeez! 最近还在亚利桑那州和伊利诺伊州推出了一款超大号Happy Balance THC-CBD比例软糖,并将于本月在新泽西州推出其Live Rosin Naturals纯素软糖。 无糖软糖、大号Happy Balance和Live Rosin完善了OGeez! 软糖的核心产品线,其中包括其标志性的水果软糖、独一无二的双层奶油软糖、市场领先的治疗性RSO软糖以及屡获殊荣的睡眠软糖。 Noonan称最新的产品发布为“无糖的锦上添花!” 关于OGeez! 作为一家领先的大麻输液公司,OGeez! 生产一些最受欢迎的软糖。该公司——由已故开拓性大麻倡导者Peggy Noonan创立——已树立了创新者和市场领导者的声誉。它致力于创造创新且令人难忘的大麻输液产品,为生活增添风味。更多信息请访问。 联系方式:Jill Noonan: 来源 OGeez! Brands本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
BOM Network Unveils Solutions to Tokenize Real-World Assets SeaPRwire

BOM Network Unveils Solutions to Tokenize Real-World Assets

Hong Kong – December 11, 2024 – (SeaPRwire) – Recently, BOM Network is proud to unveil its solutions to tokenize a wide range of real-world assets, from real estate to commodities, and use these tokens for trading, lending, or as collateral. Real-World Assets (RWA): The Bridge Between Traditional Finance and Blockchain Revolution In recent years, the crypto market has undergone remarkable growth, but its volatility and limited real-world use cases have often raised concerns. Real-World Assets (RWA) are emerging as a pivotal trend that may fundamentally reshape the blockchain and crypto space by creating a more stable and tangible connection to traditional finance. The tokenization of RWAs allows for real estate, commodities, and other physical assets to be represented on the blockchain, unlocking liquidity and expanding investment opportunities.RWAs bridge the gap between traditional assets and decentralized finance (DeFi), bringing stability, security, and trust into the often volatile crypto markets. This fusion offers several key benefits: Access to Illiquid Assets Increased Liquidity and Market Efficiency Global Access The Future of Banking and RWA Integration BOM Network is one standout project in the RWA space, focusing on integrating blockchain with traditional financial services. BOM Network’s unique approach lies in its emphasis on combining traditional banking services with the efficiency of blockchain, making it an attractive solution for institutions looking to bridge the gap between old and new financial systems. BOM Network has already established partnerships with global financial institutions, offering a scalable and secure way for investors to participate in the RWA market. Its platform is designed for both retail and institutional investors, making it a key player in the future of decentralized finance. By integrating RWAs into its ecosystem, BOM Network aims to drive the mainstream adoption of blockchain technology and create a more efficient, liquid, and globally accessible financial system. As the tokenization of RWAs gains traction, projects like BOM Network are leading the charge toward a more stable, diversified, and globally inclusive crypto market. About BOM Network BOM is the perfect bridge for capital from the real world to the Blockchain world. Meet a huge supply and demand of borrowing and lending from the real world into the cryptocurrency market. RWAs are likely to accelerate institutional adoption of blockchain technology. Moreover, the introduction of RWAs will catalyze regulatory development as governments and financial authorities adapt to this new intersection of traditional assets and blockchain technology. This convergence will bring crypto further into the mainstream, providing a fertile ground for innovation and growth. Social Links X: https://x.com/BOM_Network Telegram: https://t.me/BOMNetworkCommunity YouTube: https://www.youtube.com/@bom_network Media Contact Brand: BOM Network Contact: Media contact Email: support@bomnetwork.io Website: https://bomnetwork.io The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

云顶新耀:加速肾病领域创新 迈向全球生物制药领先地位

香港, 2024年12月11日 - (亚太商讯 via SeaPRwire.com) - 据《南华早报》报道,云顶新耀(HKEX 1952.HK)正加速实现其成为亚太地区领先生物制药企业的愿景。公司凭借强大的研发实力与卓越的商业化能力,在持续推动业务发展的同时,不断深化在全球生物制药领域的布局。近期,云顶新耀在核心商业化产品和突破性研究方面取得了一系列重要的里程碑式进展,充分体现了其在为亚洲乃至全球患者提供创新治疗解决方案方面的坚定承诺与卓越能力。这些成就不仅巩固了公司在行业中的领先地位,也进一步彰显了其致力于满足未被满足医疗需求的长期战略愿景。EVER001:肾病创新领域的突破2024年12月4日,云顶新耀宣布其自主研发且拥有全球权益的新一代共价可逆布鲁顿酪氨酸激酶(BTK)抑制剂EVER001,在1b/2a期临床试验阶段性数据中取得积极结果。本次试验聚焦原发性膜性肾病(pMN),是成人原发性肾病综合征的主要原因,存在未被满足的医疗需求。近年来,中国pMN的发病率持续上升,成为继IgA肾病(IgAN)后的第二大肾病综合征常见的病理类型。目前,中国约200万原发性膜性肾病患者,而在美国约有8万-10万患者,欧洲约8万患者,日本约4万患者,疾病负担在全球范围内日益加重,且目前全球没有获批此适应症的药物。不同于传统的共价不可逆BTK抑制剂,EVER001采用独特的共价可逆机制,结合其强大的靶点结合力与良好的安全性特征,避免持续抑制带来的毒副作用。试验结果显示,抗-PLA2R自身抗体水平在数据截止日期时已达到接近100%的下降,而早在低剂量组的24周和高剂量组的12周,抗-PLA2R自身抗体下降已超过90%。此外,在已完成36周治疗的低剂量组患者中,81.8%的患者实现临床缓解,高剂量组中已完成24周治疗的患者已有85.7%实现临床缓解。除低剂量组的1例患者外,其他所有完成36周治疗的低剂量组患者,以及所有经24周治疗的高剂量组患者分别在36周和24周都实现了免疫学完全缓解。EVER001作为一款潜在的同类最佳产品,该结果不仅显示了EVER001在pMN治疗中的高选择性、优异的药代动力学特征、良好的安全性特征以及强大的靶点结合力,还凸显了其在其他自身免疫性肾病,如狼疮性肾炎(LN)、IgA肾病、微小病变病(MCD)和局部节段性肾小球硬化(FSGS)中的广阔适应症前景。凭借广泛的适应症前景、日益增加的疾病发病率以及全球范围内的开发权益,EVER001成为具有显著商业价值的"蓝海"资产。近年来,肾病治疗领域已成为医药创新与资本投资的热点,吸引了众多跨国制药巨头的目光。以2023年为例,Vertex Pharmaceuticals斥资49亿美元收购了Alpine Immune Sciences,以获取其针对肾脏自身免疫性疾病的先进疗法。同年,诺华(Novartis)以35亿美元收购了Chinook Therapeutics,从而获得两项处于后期开发阶段的罕见肾病治疗药物。这些交易不仅凸显了全球医药行业对肾病领域的重视,也进一步验证了该领域创新治疗方案的巨大潜力和市场价值。"双轮驱动"战略推动商业化成功云顶新耀通过核心产品耐赋康(R)进一步巩固了其在肾病治疗领域的领导地位。耐赋康(R)是全球首个获得FDA批准的IgA肾病(IgAN)对因治疗药物,同时也是中国首个获得IgA肾病适应症的对因治疗药物。该药物已成功纳入2024年国家医保药品目录,这一里程碑不仅显著提升了患者可及性,还将大幅推动市场渗透率,其相关政策将于2025年1月1日正式实施。自2024年5月在中国大陆商业化上市以来,仅一个月耐赋康(R)销售额即突破人民币1.673亿元。此外,该药物还在中国澳门、中国香港、中国台湾、韩国及新加坡获批,进一步彰显了云顶新耀在全球肾病领域的专业实力与市场影响力。云顶新耀的多元化产品组合还包括氟环素类抗菌药物依嘉(R)与自身免疫疾病治疗药物伊曲莫德(VELSIPITY(R))。依嘉(R)作为全球首个氟环素类抗菌药物,在国家卫生健康委抗菌药物临床应用与耐药评价专家委员会发起并主办的"依拉环素临床应用综合评价项目"中表现卓越,临床疗效分析显示,依拉环素治疗3天时的整体有效率为91.1%,治疗结束时整体有效率为90.1%。截至2024年上半年,依嘉(R)累计销售额已达到2.33亿元,充分体现了市场对其的高度认可和接受度。在自身免疫疾病领域,伊曲莫德(VELSIPITY(R))的商业化进程取得重要进展。该产品已在中国澳门和新加坡获批上市,并通过"港澳药械通"政策率先进入粤港澳大湾区,成为云顶新耀第三款商业化产品。近期,伊曲莫德的新药上市许可申请已在中国香港获正式受理,公司计划于今年底向中国大陆递交申请,进一步释放其市场潜力。在研发领域,经过临床验证的mRNA技术平台是公司自主研发的核心部分,公司将自主研发重点转向拥有全部知识产权和全球权益的mRNA肿瘤治疗性疫苗。作为公司长期研发战略的重要支柱,该平台已实现显著突破。2024年8月,云顶新耀启动一款个性化肿瘤疫苗EVM16的研究者发起的临床试验项目(IIT),该研究由北京大学肿瘤医院和复旦大学附属肿瘤医院发起。此外,公司还在积极推进基于mRNA的体内CAR-T项目,用于癌症和自身免疫性疾病的治疗,不断拓展其研发管线的潜在应用。本周一,云顶新耀股价创下52周新高,盘中最高达49.7港元,收盘47.85港元。自中期业绩公布以来,股价已实现翻倍,充分体现了市场对公司未来发展的强烈信心。通过"双轮驱动"战略,云顶新耀持续聚焦未被满足的医疗需求,尤其在肾病等关键领域表现出色,并以EVER001等突破性疗法推动业务增长。凭借强劲的财务势头和清晰的战略规划,云顶新耀正稳步迈向可持续增长,为患者和股东创造长期价值。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership

HONG KONG, Dec 11, 2024 - (ACN Newswire via SeaPRwire.com) – As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise.Breakthroughs in Renal Disease Innovation with EVER001On December 4, Everest Medicines announced positive results in preliminary analysis of Phase 1b/2a clinical trial of EVER001, its next-generation, globally owned covalent reversible Bruton’s Tyrosine Kinase (BTK) inhibitor. The trial focuses on primary membranous nephropathy (pMN), a common pathological type of nephrotic syndrome in adults with significant unmet medical needs. The prevalence of pMN in China has been increasing, making it the second most common cause of nephrotic syndrome after IgA nephropathy (IgAN). Currently, there are approximately 2 million patients with pMN in China, 80,000 to 100,000 in the United States, 80,000 in Europe, and 40,000 in Japan,with incidence rates rising in recent years, reflecting its growing global disease burden.Unlike traditional covalent irreversible BTK inhibitors, EVER001 employs a novel covalent reversible mechanism that combines strong target binding with excellent selectivity, significantly reducing off-target toxicity. Positive results in preliminary analysis revealed promising outcomes, with over 90% reductions in anti-PLA2R antibodies and substantial improvements in proteinuria. Additionally, patients in the low-dose cohort who have completed 36 weeks of treatment, 81.8% achieved overall clinical remission, and 91% achieved immunological complete remission. In the high dose cohort, 85.7% patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24. With no currently approved treatments for pMN, EVER001 represents a potentially best-in-class therapeutic candidate. These results highlight EVER001’s potential to deliver best-in-class efficacy and safety, making it a promising treatment not only for pMN but also for a range of other autoimmune glomerular diseases, including lupus nephritis (LN), IgAN, Minimal Change Disease (MCD), and focal segmental glomerulosclerosis (FSGS).With broad indication potential, rising disease prevalence, and Everest Medicines’ global rights, EVER001 represents a high-value asset in a “Blue Ocean” area with significant commercial potential. Kidney disease therapeutics have become a hotspot for innovation and investment in recent years, attracting major multinational pharmaceutical companies. For example, Vertex Pharmaceuticals acquired Alpine Immune Sciences this April for $4.9 billion to access its kidney autoimmune disease therapies. Similarly, Novartis acquired Chinook Therapeutics in June 2023 for $3.5 billion, gaining access to two late-stage treatments for rare, severe chronic kidney diseases.Driving Commercial Success with a Dual-Engine StrategyEverest Medicines continues to strengthen its leadership in nephrology with NEFECON(R), the first FDA-approved treatment for IgAN and the first etiological therapy for IgAN in China. Its inclusion in the 2024 National Reimbursement Drug List (NRDL) marks a significant milestone, enhancing patient accessibility and driving market penetration starting January 1, 2025. Since its commercial launch in May 2024, NEFECON(R) has generated RMB167 million in sales within its first month. The product is also approved in Macau, Hong Kong, Taiwan, South Korea, and Singapore, further cementing Everest’s expertise in nephrology.Everest’s diversified portfolio also includes XERAVA(R) and VELSIPITY(R). XERAVA(R), a novel broad-spectrum antibiotic, demonstrated an overall effectiveness rate of 90.9% after three days of treatment in the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", contributing RMB134 million in revenue in H1 2024. VELSIPITY(R), approved under the "Hong Kong and Macau Medicine and Equipment Connect" policy, is now available in three designated medical institutions within the Greater Bay Area. It has also received approvals in Macau and Singapore, with an NDA accepted in Hong Kong and plans for an NDA submission in Mainland China by year-end.Everest is accelerating innovation through its proprietary mRNA platform, a cornerstone of its long-term R&D strategy. In August 2024, Everest launched an Investigator-Initiated Clinical Trial for EVM16, a personalized mRNA cancer vaccine, at Peking University Cancer Hospital and Fudan University Cancer Hospital. The company is also advancing mRNA-based in vivo CAR-T programs for cancer and autoimmune diseases, expanding its pipeline’s potential.As of now, Everest Medicines reached a 52-week high of HKD 49.7, closing at HKD 47.85. Since announcing its mid-year results, the stock price has more than doubled, reflecting strong investor confidence. With its dual-engine strategy, Everest has positioned itself as a rising leader in the global biopharmaceutical industry, focusing on unmet medical needs, particularly in renal diseases, and breakthrough therapies like EVER001. Supported by strong financial momentum and a clear vision, Everest is poised for sustainable growth and lasting value for patients and shareholders. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program JCN Newswire

Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program

Tokyo and Kawasaki, Japan, Dec 11, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited, Toyo University Incorporated Educational Institution (Toyo University) and Kokoro Balance Research Institute today announced the commencement of a field trial on December 3, 2024, to develop a Training Program for Coping with Customer Aggression. This program leverages AI and incorporates insights from criminal psychology and mental health to tackle the growing societal issue of customer harassment, i.e., unreasonable or abusive behavior directed at staff by customers and clients.The program utilizes the “AI Tool for Experiencing Customer Aggression” developed using Fujitsu's generative AI technology, behavior change support technologies and Toyo University's expertise in criminal psychology. Fujitsu’s AI tool provides interactive feedback through the use of AI avatars and clarifies actions that can be taken to enhance participants' customer harassment response skills. To evaluate the program's effectiveness, Kokoro Balance Research Institute will leverage its mental health expertise to develop new psychological scales measuring customer service skills, stress management, and overall customer harassment response capabilities. Furthermore, the research partners will carry out a field trial with call center employees at Fujitsu Communication Services Limited (CSL), analyzing changes in participants' customer service skills, stress management, engagement, and subjective productivity to ensure the program's scientific validity.The full program is targeted for launch in fiscal 2025 with the goals of reducing the psychological burden of working people in customer service roles and contributing to the creation of safe and supportive work environments.BackgroundCustomer harassment has become a serious social issue. A recent survey revealed that 46.8% of service industry workers have encountered customer harassment in the past two years, with nearly half experiencing lasting physical and mental health consequences.In response, the Ministry of Health, Labour and Welfare added mental health issues related to customer harassment to its work-related injury recognition criteria in September 2023. Furthermore, the Tokyo Metropolitan Assembly passed Japan's first customer harassment prevention ordinance in October 2024. The growing national and local government efforts are driving increased organizational responsibility for employee protection.Field Trial PeriodDecember 3, 2024 to March 31, 2025Figure 1: Overview diagram of the field trial Comment from Akiko Yamada, Head of the Converging Technologies Laboratory of Fujitsu Research, Fujitsu Limited:We have been pursuing research in converging technologies, combining cutting-edge digital technology with knowledge from humanities and social sciences to solve various social issues. This new initiative combines generative AI, behavioral change support technology, criminal psychology, and mental health expertise to tackle the significant social problem of customer harassment and secure the well-being of working people.Comment from Prof. Masayuki Kiriu, Dean, Faculty of Sociology, Toyo University:By incorporating psychological scales and stress measurement indicators into the "AI Tool for Experiencing Customer Aggression”, we expect to create a practical and effective customer harassment response training program for customer service personnel. This will significantly contribute to solving current customer harassment issues. We anticipate the emergence of new social contributions through converging technology in this pilot program.Comment from Kyoko Shimada, Representative Director, Kokoro Balance Research Institute:Customer harassment can inflict deep emotional wounds on employees. While eradication may be impossible, we can reduce its impact through organizational efforts. This research aims to strengthen organizations by focusing on employee mental health and response capabilities. By using globally recognized psychological scales and effective evaluation criteria, we aim to make this program scientifically sound, useful, and applicable for employees.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiriesToyo UniversityToyo University General Affairs Department, Public Relations DivisionPhone: 03-3945-7571Reception hours: 9:00-18:00 JST (excluding Saturdays, Sundays, holidays, and university-designated holidays)E-mail: mlkoho@toyo.jpKokoro Balance Research InstituteE-mail: info@kokorobalance.jp Copyright 2024 JCN Newswire via SeaPRwire.com.
More
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China SeaPRwire

China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China

SHENZHEN, CHINA, Dec 9, 2024 – (ACN Newswire) – On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits. According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand. The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China. With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS’s commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. References: 1. The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/ 2. Data from the Digestive Endoscopy Branch of the Chinese Medical Association 3. Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-00164 4. National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htm CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
More
FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution SeaPRwire

FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution

Nassau, the Bahamas – December 11, 2024 – (SeaPRwire) – FxPro Group, a global leader in financial services and trading, has launched BankPro, a cutting-edge Private Digital Bank designed to redefine digital financial solutions for individuals and corporations. BankPro combines private banking services with advanced investment and trading capabilities, offering clients a seamless, all-in-one application tailored to their financial needs. The launch of BankPro underscores FxPro Group’s commitment to innovation and excellence, leveraging its 25 years of expertise and $120 million in Tier 1 company capital to introduce a next-generation digital banking solution. BankPro is regulated by the Central Bank of The Bahamas and operates with the highest standards of security and compliance. Key Features of BankPro: Multi-Currency Accounts BankPro provides access to over 24 currencies, enabling effortless international transactions at competitive exchange rates. Clients can manage their finances globally with a single account designed for both personal and corporate use. Visa Platinum Cards Clients can access exclusive Visa Platinum cards, offering customizable spending limits, global acceptance, and enhanced security. Additionally, instant virtual cards provide a secure and efficient solution for online transactions, making BankPro a versatile option for all financial activities. Global Banking with Flat Fees BankPro simplifies international banking with flat-fee structures, ensuring transparent and predictable costs. This approach is particularly advantageous for high-value transactions, providing clarity and value for clients engaged in global business and personal finance. Comprehensive Investment and Trading Platform BankPro integrates investment and trading capabilities, allowing clients to manage and grow their portfolios within the same platform. Key features include: Investing in over 2,100 Stocks and ETFs: Clients gain access to major exchanges, including NYSE, Nasdaq, LSE, XETRA, and Euronext. Real-Time Market Data: Active subscriptions include free live pricing from Nasdaq and LSE. Through FxPro Global Markets Ltd., clients can also trade over 200 Derivatives across Forex, Commodities, Metals, Indices, Stocks, and ETFs, enabling portfolio diversification and risk management. Corporate Banking Solutions BankPro offers tailored services for businesses, including multi-currency accounts, streamlined expense management tools, and advanced treasury management solutions. Corporate clients benefit from high-spending Visa Platinum cards, detailed reporting tools, and access to flexible investment options. A Strong Foundation in the Bahamas BankPro operates from its state-of-the-art headquarters in Lyford Cay, Nassau. The facility reflects the company’s commitment to The Bahamas as a central hub for its operations. The company also has an office in the City of London, UK. As a fully regulated entity, BankPro prioritizes security and reliability, holding a professional membership with the Association of International Banks and Trust Companies. The company’s regulatory foundation ensures robust protection for clients, complemented by advanced digital onboarding tools and fraud prevention measures. These features, combined with the FxPro Group’s legacy of excellence, make BankPro a trusted partner for financial services. About FxPro Group With 25 years of experience, the FxPro Group is a global leader in financial services, offering trading solutions across Forex, Commodities, and more. With a presence in over 170 countries and $200+ million invested in elite sponsorships, FxPro has earned over 120 industry awards for its innovative technology and reliable services. The launch of BankPro marks the Group’s expansion into digital private banking, combining its expertise in trading with cutting-edge financial solutions designed for the modern client. To know more please contact +1 242 603 2226. Media Contact Brand: BankPro Limited Contact: Media team Email: info@bankpro.com Website: https://www.bankpro.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

顺丰控股进军港股 书写国际化发展新篇章

香港, 2024年12月10日 - (亚太商讯 via SeaPRwire.com) - 据经济日报报道,随着全球企业供应链的重塑、中国企业出海以及跨境电商的推动,市场对更高效、更灵活、更综合的物流服务的需求不断攀升。顺丰控股股份有限公司(「顺丰控股」,股份代号:6936.HK)以其独特的业务模式和强大的网络优势,积极布局国际物流服务,投身于时代革新发展的浪潮中。根据弗若斯特沙利文,按2023年收入计,顺丰控股是中国及亚洲最大的综合物流服务提供商,也是全球第四大综合物流服务提供商,仅次于联合包裹服务公司(UPS)、敦豪(DHL)和联邦快递(FedEx)。公开资料显示,顺丰控股连续多年位居《财富》世界500强企业之列。2024年,公司获评《财富》最受赞赏的中国公司第二位,且连续8年上榜「《财富》最受赞赏的中国公司」。11月27日,顺丰控股登陆港交所,掀开国际化发展新篇章。夯实物流基础网络 持续迎来盈利兑现顺丰控股最早于2010年即开始运营国际业务,主要服务中国客户的出境物流需求。如今,随着中国企业出海,国际供应链蕴含着重大转型机遇。2021年,公司携手嘉里物流,进一步强化了在东南亚的本土及跨境快递、国际供应链和国际货代能力。通过与嘉里物流的融通,其国际综合物流能力和客户基础得到进一步强化,为实现国际拓展的战略和愿景提供了重要助力。根据弗若斯特沙利文报告,按国际收入计,2023年顺丰的国际业务规模已在所有亚洲综合物流服务提供商中排名第一。值得关注的是,经过多年投入后,顺丰控股已度过资本开支的高峰期,迎来更高质量增长周期。一方面,业务规模扩张持续摊薄基础设施边际成本,提升其营业利润率。另一方面,公司新业务陆续进入"收获期",提供公司盈利弹性。具体而言,经济产品体系升级,助力利润稳步增长;大件业务于2022年净利润转盈,2023年在降本提效作用下盈利能力持续增厚;同城业务于2023年首次实现全年盈利,2024年延续高增长。得益于此,顺丰控股盈利能力持续增强,2024年前三季度,其收入同比增加9.4%,净利润同比增加28.0%。净利率达到3.7%,同比提升了0.5个百分点。未来,在上述因素的共同推动下,公司盈利能力有望进一步增强。加速推进国际业务 打开中长期成长空间对于顺丰控股而言,从亚洲到全球,是其发展的必然。为此,公司积极参与建设鄂州货运枢纽,作为亚洲第一、全球第四座以货运为主的物流枢纽,鄂州货运枢纽的投产将进一步扩大公司与同业在配送时效以及网络方面的差异化优势,促进公司降本增效,为国际业务拓展奠定了坚实的基础。随着位于鄂州货运枢纽的分拣及转运中心投入运营,凭借丰富的产品组合、综合的全球能力、并购经验、卓越的运营及精益的成本管控,顺丰控股能够有效整合市场并把握国内外的市场机遇。顺丰控股高管曾表示,赴港上市是出于国际化的长远考虑,最主要目的是利用全球化资本,实现规模快速扩张。本次上市,顺丰控股计划将募集资金的45%用于加强其国际及跨境物流能力,此将进一步提升公司国际产品的广度及深度,助力公司国际业务加速拓展。同时,H股上市也有助于提升公司品牌影响力及市场竞争力。在丰富的物流网络、领先的成本优势和综合物流能力的支撑下,顺丰控股有望抢占更大的全球市场份额,推动公司投资价值的不断增长。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
[Macao Products Receiving Wide Acclaim] Macao Companies Achieved Remarkable Success with Doubled Sales and Over 50 Business Matching Negotiations at the Singapore Food Expo SeaPRwire

[Macao Products Receiving Wide Acclaim] Macao Companies Achieved Remarkable Success with Doubled Sales and Over 50 Business Matching Negotiations at the Singapore Food Expo

The four-day “Asia Pacific Food Expo 2024” successfully concluded on Monday (Dec 9th), with over 50 business matching negotiations taking place at the Macao Pavilion. Macao exhibitors are satisfied with the outcomes, as “Made in Macao” and “Macao Brand” products have garnered substantial repurchases and inquiries. “Sales figures for a single day at the event surpass those typically seen in Macao on weekdays”. The heightened demand at the event has elevated the popularity of Macao products to a peak, establishing them as the preferred choice among Singaporean and international businessmen. Moreover, some exhibitors have successfully connected with the local supermarkets and food agents through interactions. Furthermore, some businessmen have shown optimism regarding Macao’s business environment and the significant potential of Halal catering market in general. They engaged in profound discussions with Macao enterprises on-site and expressed their intentions to establish a presence in Macao. [caption id="attachment_3184" align="aligncenter" width="1400"] Pictures:Alvin Tan Sheng Hui, Singaporean Minister of State for Trade and Industry, and other guests visited the Macao Pavilion[/caption] In Singapore, Ms. Elaine Wong, Member of Board of Directors of Macao Commerce and Investment Promotion Institute (IPIM), met with Honorary President Edward Liu and Executive Director Jan Tan of the Asian Federation of Exhibition and Convention Associations (AFECA) to promote the MICE advantages of Macao and Hengqin, and invited AFECA to hold conventions and exhibitions in Macao and Hengqin. Mr. Edward Liu expressed his intention to visit Macao and Hengqin for an inspection tour in 2025. Established in Singapore in 2005, AFECA currently has about 155 members, which are mainly the MICE industry associations in Asia. [caption id="attachment_3185" align="aligncenter" width="1492"] Pictures:IPIM representatives met with AFECA representatives[/caption] The “Consumption + Negotiation” Integrated Exhibition Aids Enterprises in Connecting with International Business Opportunities Organised by the Singapore Food Manufacturers’ Association, the “Asia Pacific Food Expo 2024” has an exhibition area of about 10,000 square meters. The event has drawn the participation of over 200 exhibitors from mainland China and Singapore, encompassing upstream, midstream and downstream industrial chain enterprises in the food and beverage industries. IPIM and the Industrial Association of Macau set up the Macao Pavilion, for the first time, at the “Asia Pacific Food Expo”, and organised the participation of 24 Macao SMEs and over 250 “Made in Macao”, “Macao Brand” products, of which nearly 80% were Halal-certified products or the distinguished “M Brand” quality products. [caption id="attachment_3186" align="aligncenter" width="1393"] Pictures:Crowds at the Macao Pavilion of the “Asia Pacific Food Expo 2024”[/caption] [caption id="attachment_3187" align="aligncenter" width="1399"] Pictures:IPIM and the Industrial Association of Macau set up the Macao Pavilion at the “Asia Pacific Food Expo 2024” for the first time to promote Macao products[/caption] [caption id="attachment_3188" align="aligncenter" width="1400"] Pictures:Macao products were very popular at the event[/caption] [caption id="attachment_3189" align="aligncenter" width="1400"] Pictures:Macao products were very popular at the event[/caption] [caption id="attachment_3190" align="aligncenter" width="1400"] Pictures:Local Internet influencers were invited to promote the Macao Pavilion[/caption] Throughout the four-day event, Macao exhibitors, and the buyers and visitors from around the globe all benefited significantly. According to the Macao enterprises, the diverse customer sources of the Expo enable them to swiftly comprehend and access the latest market trends, and to grasp the new consumption patterns of international customers. Furthermore, the “consumption + negotiation” integrated exhibition can function as a platform for testing the products and establishing business networks. Local Internet influencers were also invited to promote Macao companies’ brands and their charms at the Macao Pavilion. [caption id="attachment_3191" align="aligncenter" width="1400"] Pictures:Enterprises were exploring business opportunities at the Macao Pavilion[/caption] [caption id="attachment_3192" align="aligncenter" width="1400"] Pictures:The check-in booths featuring elements from Portuguese-speaking countries at the Macao Pavilion[/caption] Leveraging Insights from the Global Halal Food Sector to Craft the Golden Business Card for Halal Food in Macao At the event, exhibitors were delighted to witness the positive reception of Macao’s halal food by the visitors. Through the exhibition, they have recognised significant business prospects in Singapore and other halal food markets. They will leverage insights from the Singapore’s Halal food to upgrade Macao’s halal food production, in order to further enrich the experience of international visitors to Macao, thereby crafting Macao’s golden business card. [caption id="attachment_3193" align="aligncenter" width="1400"] Pictures:The on-site coffee brewing demonstration at the Macao Pavilion attracts crowds of visitors[/caption] [caption id="attachment_3194" align="aligncenter" width="1858"] Pictures:The on-site coffee brewing demonstration at the Macao Pavilion attracts crowds of visitors[/caption] Some visitors praised the layout and arrangement of the Macao Pavilion, which could let them fully feel the charm of Macao and quickly grasp the latest business information of Macao and Hengqin. The accurate connection with Macao enterprises for “one-on-one” negotiations also strengthened their intention to invest in Macao and Hengqin.
More
【澳门产品广获好评】澳企在新加坡参展喜获双收  销量翻倍促逾50场配对洽谈 SeaPRwire

【澳门产品广获好评】澳企在新加坡参展喜获双收 销量翻倍促逾50场配对洽谈

一连四天的“亚太国际食品展2024”于今(9)日圆满闭幕。澳门馆内促逾50场配对洽谈,展商们满意成效,“澳门制造”、“澳门品牌”的产品获得高回购及高查询,“单日货品销量至少是澳门平日的翻倍”,连日热销让澳门产品的知名度推至高点,成为新加坡以至国际客商的“心头好”;亦有展商成功连线当地商超、代理商等。此外,有与会客商看好澳门营商环境以及清真市场发展潜力庞大,即场与澳门企业开展深入交流,并有落户澳门计划。 [caption id="attachment_3184" align="aligncenter" width="1400"] 图片说明:新加坡贸易与工业部政务部长陈圣辉等嘉宾参观澳门馆[/caption] 赴新加坡期间,澳门特别行政区招商投资促进局委员黄伊琳会面亚洲展览会议协会联盟(AFECA)Honorary President Edward Liu及Executive Director Jan Tan,推介澳琴会展优势,亦诚邀该会赴澳琴办展办会。Edward Liu透露2025年有计划赴澳琴考察。AFECA于2005年在新加坡成立,现有会员单位约155个,主要来自亚洲地区的会展行业协会。 [caption id="attachment_3185" align="aligncenter" width="1492"] 图片说明:招商投资促进局代表会面亚洲展览会议协会联盟代表[/caption] “消费+洽商”一体展会助企业联通国际商机 “亚太国际食品展2024”由新加坡食品厂商联合会主办,展览面积约一万平方米,吸引来自中国内地、新加坡等逾200家展商参与,涵盖食品及饮料等行业的上中下游产业链企业。招商投资促进局联同澳门厂商联合会首次设置澳门馆,组织24家澳门中小企展销展示250多款“澳门制造”、“澳门品牌”产品,当中近80%澳门展商产品持清真认证或及“M唛”澳门产品优质认证。 [caption id="attachment_3186" align="aligncenter" width="1393"] 图片说明:“亚太国际食品展2024”的澳门馆人流络绎不绝[/caption] [caption id="attachment_3187" align="aligncenter" width="1399"] 图片说明:澳门特别行政区招商投资促进局联同澳门厂商联合会首次在“亚太国际食品展2024”设置澳门馆推广澳门产品[/caption] [caption id="attachment_3188" align="aligncenter" width="1400"] 图片说明:澳门产品受与会客商追捧[/caption] [caption id="attachment_3189" align="aligncenter" width="1400"] 图片说明:澳门产品受与会客商追捧[/caption] [caption id="attachment_3190" align="aligncenter" width="1400"] 图片说明:澳门馆内安排当地的网络达人穿梭走访展位[/caption] 四天展会澳门展商及世界各地与会客商均收获满满。有澳门企业代表指该展会客源多样,有助快速了解及获取市场最新动态,掌握客群的新型消费模式,而且展会集消费及洽商为一体,成为企业视作产品“试水”和建立商业网络的绝佳平台。澳门馆内还安排了当地的网络达人穿梭走访展位,助企业宣传推广品牌及产品魅力。 [caption id="attachment_3191" align="aligncenter" width="1400"] 图片说明:客商们在澳门馆内拓展商机[/caption] [caption id="attachment_3192" align="aligncenter" width="1400"] 图片说明:澳门馆内结合葡语国家元素打卡位吸引[/caption] 取经各地清真食品之长打造澳门清真食品新名片 同时展商喜见澳门清真食品获得不少客商好评,通过实地参展,了解到新加坡等清真食品市场商机巨大,会借镜新加坡清真等食品优点,融入到澳门清真食品升级箇中“内涵”,进一步满足并丰富国际客商的游澳体验,继而“升呢”成为澳门新名片。 [caption id="attachment_3193" align="aligncenter" width="1400"] 图片说明:澳门馆内咖啡佳酿即场制作示范引人流[/caption] [caption id="attachment_3194" align="aligncenter" width="1858"] 图片说明:澳门馆内咖啡佳酿即场制作示范引人流[/caption] 有与会客商点赞展馆布局及安排到位,充分感受到澳门魅力的同时,亦能快速掌握澳琴最新营商信息,并叠加精准对接澳门企业开展“一对一”洽谈,加强了在澳琴投资的意欲。
More
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections ACN Newswire

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

KNOXVILLE, Tenn., Dec 10, 2024 - (ACN Newswire via SeaPRwire.com) - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico."RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide.""VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.About VisiRoseVisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.About Bascom Palmer Eye InstituteThe Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.About Provectus BiopharmaceuticalsProvectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.For Media Inquiries:VisiRose, Inc.E: contact@visirose.comW: visirose.comContact:VisiRose, Inc.Dominic RodriguesActing Chief Executive OfficerE: rodrigues@visirose.comSOURCE: VisiRose Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform JCN Newswire

Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform

TOKYO, Dec 10, 2024 - (JCN Newswire via SeaPRwire.com) - The Association for Promotion of Sustainable Finance Platform (AP-SFPF) and Hitachi, Ltd. (Hitachi) today announced that we will begin providing the first template feature adapted to the IFRS sustainability disclosure standards in Japan (IFRS S1 and S2*1) formulated by the International Sustainability Standards Board (ISSB), on the Sustainable Finance Platform - Engagement Support Service (SFP-ESS), a digital platform that promotes ESG investing by establishing seamless connections between asset management companies and listed companies.Specifically, Hitachi's SFP-ESS, developed under license from the IFRS Foundation, will be enhanced with a templatedesigned to facilitate reporting in accordance with IFRS S1 and S2 and the SASB Standards*2 (Templates). AP-SFPF will offer the Templates to asset management companies and listed companies in Japan as the service provider.By starting to provide the Templates, AP-SFPF and Hitachi will support listed companies in Japan in their disclosure of information in conformance with IFRS S1 and S2 and communication between listed companies and assetmanagement companies. This will enable global institutional investors to properly evaluate sustainability-conscious corporate activities in the ESG perspective and contribute to the enhancement of the companies' corporate value.AP-SFPF is a general incorporated association that was established to connect diverse stakeholders andpromote effective and efficient communication, solving issues and considering projects to contribute to the continued development of the ESG market. It was established in July 2023 by eight companies, which mainly include financial institutions: MS&AD Insurance Group Holdings, Inc., Sompo Japan Insurance Inc., Tokio Marine & Nichido Fire Insurance Co., Ltd., Nippon Life Insurance Company, Hitachi, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation, and MUFG Bank, Ltd.Background of the start to adapt the SFP-ESS for IFRS S1 and S2Recently, investors' interest in companies' sustainability initiatives has been growing and companies are implementing sustainability initiatives and disclosing information about them. However, there are various disclosure standards in Japan and global. This has created an issue regarding disclosures. The people in charge of disclosing information,especially people at listed companies engaging in business globally, are not sure which standards to refer to and unable to determine investors' expectations regarding the disclosure of information, in addition to being short of resources. To solve this situation, the ISSB announced IFRS S1 and S2 in June 2023 as global baseline standards forthe disclosure of sustainability-related information.In Japan, the Sustainability Standards Board of Japan (SSBJ) is formulating the Japanese version of S1 and S2 (the SSBJ standards), which are made to comply with all of the requirements of IFRS S1 and S2, the standards fordisclosing sustainability-related informationin Japan. The finalized standards are planned to be published by March 2025. In addition, the Financial ServicesAgency made it mandatory to disclose sustainability-related information in securities reports in the fiscal year ended March 31, 2023. It is also considering the gradual application of the SSBJ standards to companies listed on the PrimeMarket starting in the fiscal year ending March 31, 2027. Therefore, listed companies are facing urgent tasks, such asthe collection of sustainability-related information and the development of a disclosure process in line with IFRS S1and S2, to prepare for the disclosure of information becoming mandatory in the future and to enhance their corporate value.In response, AP-SFPF exchanged opinions with more than 100 companies, including asset management companiesand listed companies, and began to offer a beta version of the SFP- ESS and verify its value in October 2023 to reduce the workload of the people at listed companies in charge of disclosing information and promote ESG investingin Japan. By using the Templates to adapt the SFP-ESS to IFRS S1 and S2, AP-SFPF and Hitachi will help listed companies smoothly disclose ESG information and contribute to improving their corporate value.Outline of SFP-ESSThe SFP-ESS is a two-sided platform on which asset management companies and listed companies making ESG investments are connected seamlessly to deepen their mutual understanding of each other. Asset managementcompanies present their needs regarding the ESG information it expected that listed companies disclose in line with theSASB*2 Standards. Listed companies refer to this registered information, which enables them to understand the needs of asset management companies and use the information when formulating their disclosure policies.Listed companies enter their data into the platform and send it, publishing it alongside comments by following the disclosure items in the Templates. This facilitates asset management companies' side-by-side comparison of listedcompanies as the viewers and also enables them to understand data, including the details.Features of the Templates adapted to IFRS S1 and S2Regarding IFRS S1 and S2, documents explaining the disclosure standards themselves, the IFRS Sustainability Disclosure Taxonomy*3, and support materials including a guide for the voluntary application of ISSB Standards havebeen published. However, Japanese documents are limited, and each company is left to decide how they will disclose the information they should disclose in their integrated reports and other reports. To support the practical tasks done by these listed companies, the Templates come with an input interface available in Japanese, so that digital data can be entered and saved on the platform in accordance with definitions in the taxonomy. Specifically, the Templates helplisted companies understand and respond to IFRS S1 and S2 using the following three features.1. Disclosure items classified into three categories (major categories, intermediate categories, and subcategories)The IFRS Sustainability Disclosure Taxonomy information is classified in detail into four core classifications (governance, strategy, risk management, and metrics and targets). However, the hierarchical structure differs from item to item. In response, a creative measure was devised to streamline data entry by the people in charge ofthe disclosure of information at listed companies by classifying the information into major categories,intermediate categories and subcategories visualizing the hierarchical structure of the information. This helps the people in charge of disclosing information at companies understand information collection based on the definitions in IFRS S1 and S2 without difficulty.2. Supplementary information from the IFRS Foundation regarding each disclosure item is provided when viewing the Templates.The IFRS Foundation, provides application guidance which companies may want to refer to when entering information into the Templates.3. Tables styles and options enabling an intuitive understanding of the information that needs to be disclosed are availableOptimal table styles are provided on an item-by-item basis to enable people to intuitively understand and enter the information required for each disclosure item. For example, there is an appropriate answer space for itemsthat are yes or no questions. In addition, for items which require that risks be described, there is a multiple-choice section about the type of risk (physical or transition) and the time frame (short, medium, or long term), in addition to the space for describing the risk. This prevent the omission of information or the provision of insufficient information.Future developmentMoving forward, AP-SFPF and Hitachi will broadly expand the SFP-ESS with the Templates to listed companies andtalk with multiple listed companies preparing to comply with IFRS S1 and S2 ahead of others. It will thus collect opinionsand requests regarding the improvement of the convenience of the Templates and develop the Templates so that we are more useful and adapted to IFRS S1 and S2.We will also work to functionally enhance the SFP-ESS in addition to developing the Templates. Specifically, they moveforward with consideration and development to provide service features which will be needed in the promotion ofthe disclosure of information, dialogue, and engagement between asset management companies and listedcompanies, such as a feature enabling asset management companies to register their information disclosure needs, and to release these features one by one. We also plan to incorporate the finalized SSBJ standards which will be published by the SSBJ by March 2025.Speaking at Director of Earned Revenue, IFRS Sustainability, Eli Reisman, said:“The IFRS Foundation welcomes Hitachi as a licensee of its standards. The IFRS Foundation encourages companiesvoluntarily applying IFRS S1 and IFRS S2, in addition to the progress being made towards regulatory adoption or other use of IFRS S1 and IFRS S2 happening in 25+ jurisdictions globally. In order to facilitate this corporate disclosure, it’s imperative that various services and tools integrate the ISSB standards to support this process."Yasuki Imai, Vice President and Executive Officer, Head of Digital Systems & Services APAC Business, and CEO of Financial Institutions Business Unit, Hitachi, Ltd, said:“In line with this approach to sustainability reporting, Hitachi and its only reseller of SFP-ESS, The Association forPromotion of Sustainable Finance Platform, aim to facilitate the application of IFRS S1, S2, and SASB standards and provide guidance on industry-specific disclosures through the SFP-ESS platform: SFP-ESS is a digital platformdesigned to support companies in their sustainability reporting efforts. This tool is intended to assist companies in navigating the reporting process, with the goal of enhancing the standardization and relevance of ESG reporting.”AP-SFPF member company, Managing Executive Officer, Group Chief Sustainability Officer (CSuO), MS&AD Insurance Group Holdings, Inc., Naomi Motojima said:“MS&AD Insurance Group Holdings, Inc. engages in investment, lending and insurance underwriting activities in consideration with ESG as a signatory to Principles for Sustainable Insurance (PSI) and the Principles for ResponsibleInvestment (PRI). We consider “Symbiosis with global environment ~Planetary Health~” as an important issue forMS&AD group, and we are working on realizing “Action on climate change” and “Improvement of sustainability of natural capital” comprehensively to enhance the resilience of society. We help to solve ESG issues including climate change through insurance underwriting, investment and lending, and of course we also work to reduce our own Greenhouse gas (GHG) emissions. We regard them as missions that we have as an insurance and financing serviceprovider. SFP-ESS is a platform that increases the mutual understanding of companies and financial institutions regarding ESG information disclosure. We hope that using the disclosure templates adapted to S1 and S2, which will be newly implemented, will facilitate the disclosure of information related to companies' ESG activities and lead to investors appropriately evaluating the companies. Further, from the standpoint of an investor, we find the developmentof a platform which enables users to compare the information disclosed by companies using a same index beneficial in the activities for the appropriate evaluation of the activities of the companies. Therefore, we welcome the release of the template feature.”*1 Disclosure standards announced by the IFRS Foundation in June 2023. The standards consist of IFRS S1 (General Requirements for Disclosure of Sustainability-related Financial Information) and IFRS S2 (Climate-related Disclosures).*2 The Sustainability Accounting Standards Board (SASB) Standards provide industry-specific ESG disclosure guidance focused on financial materiality. As of August 2022, the International Sustainability Standards Board (ISSB) of the IFRS Foundation assumed responsibility for the SASB Standards.*3 The IFRS Sustainability Disclosure Taxonomy is a framework for digitally tagging sustainability-related financial disclosures Its goal is to digitalize informationand facilitate investors' and stakeholders' comparison and assessment of companies' sustainability performanceSFP-ESS websitehttps://sfp-ess.org/en/service/About the Association for Promotion of Sustainable Finance Platform (AP-SFPF)The AP-SFPF was established in July 2023 to solve issues and consider projects, with financial institutions playing a leading role, to create new value and contribute to the continued development of the ESG market, eventually resultingin the sustainable development of society through the connection of various stakeholders to each other and the provision of a platform which will facilitate efficient and effective communication related to ESG issues.Member companies: MS&AD Insurance Group Holdings, Inc., Sompo Japan Insurance Inc., Tokio Marine & NichidoFire Insurance Co., Ltd., Nippon Life Insurance Company., Hitachi, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation., MUFG Bank, Ltd.Representative: Yoshihiro Kanaoka, Representative Director Location: 1-6-1 Marunouchi,Chiyoda-ku, Tokyo 100-8220, Japan Corporate website: https://sfp-ess.org/en/About Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company's website at www.hitachi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.
More
Fujitsu drives business process improvement at Mitsubishi Electric Engineering using SAP Signavio(R) JCN Newswire

Fujitsu drives business process improvement at Mitsubishi Electric Engineering using SAP Signavio(R)

Fujitsu today announced that it has provided Mitsubishi Electric Engineering with process visualization and analysis services utilizing the process mining(1) capabilities of “SAP Signavio®”(2), a platform that supportsbusiness transformation. Fujitsu consultants also identified areas requiring improvement and offered recommendations for process optimization.Mitsubishi Electric Engineering implemented its current system using SAP S/4HANA® in 2022 and planned a system upgrade for 2025. To optimize costs and efficiency before the upgrade, the company evaluated the effectiveness of its key business processes, such as sales and procurement, focusing on areas for improvement in operational quality and process standardization.To support this evaluation, Fujitsu employed its visualization and analysis service, which continuously monitors, analyses, and evaluates the effects of the current system's implementation. By visualizing the entire business process using log data from the current system, Fujitsu identified bottlenecks and process inconsistencies. Fujitsu consultants, with their deep understanding of SAP solutions, then used this information to propose process improvements.These improvement proposals were then discussed and refined in workshops with Mitsubishi Electric Engineering, leading to a clear identification of business challenges and improvement strategies. This data-driven approach, compared to traditional consulting methods relying solely on client interviews, enabled a rapid clarification of the current situation. This shortened the usual six to twelve-month evaluation phase to approximately one month, allowing more time for in-depth discussions on core business issues.Fujitsu will continue to support Mitsubishi Electric Engineering's process improvement initiatives. Through this collaboration, Fujitsu aims to help various companies achieve continuous process improvement and enhance their ability to adapt to changing business environments.(1) Process mining: Analytical method for discovering, monitoring, and improving actual processes based on easily accessible event logs from existing information systems.(2) SAP Signavio®: Platform provided by SAP SE (Germany) that supports business process management.Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030.Fujitsu’s purpose — “to make the world more sustainable by building trust in society through innovation” — is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.
More
以色列战机猛攻叙利亚,据报道军队深入叙利亚境内
“` Latest News

以色列战机猛攻叙利亚,据报道军队深入叙利亚境内 “`

(SeaPRwire) - 叙利亚大马士革——叙利亚反对派战争监测组织周二表示,以色列发动了一波空袭,同时其军队深入叙利亚境内,距离首都不到25公里(15英里)。以色列否认其部队正在向大马士革推进。 美联社驻大马士革记者听到该市及其郊区在夜间和周二遭到猛烈的空袭。网上流传的照片显示,导弹发射器、直升机和战机被摧毁。 由叙利亚解放组织(Hayat Tahrir al-Sham,简称HTS)领导的叛乱组织——目前控制着大马士革——尚未立即发表评论。 以色列此前曾表示,在1973年中东战争后建立的缓冲区已被摧毁,它表示此举是为了防止在巴沙尔·阿萨德总统被推翻后发生袭击。 以色列还表示,它正在打击可疑的化学武器地点和重型武器,以防止它们落入极端分子手中。以色列官员很少承认个别袭击事件。 以色列长期以来在与邻国的战争中夺取领土,并以安全为由这样做。以色列在1967年中东战争中从叙利亚手中夺取了戈兰高地,并在未经国际社会承认的情况下将其吞并,美国除外。 总部位于英国的叙利亚人权观察组织密切跟踪了自内战爆发近14年以来的冲突,该组织表示,自周末叛军推翻阿萨德以来,以色列已在全国各地进行了300多次空袭。 人权观察组织和总部位于贝鲁特的Mayadeen电视台(在叙利亚有记者)表示,以色列军队正在沿着叙利亚与黎巴嫩的边界推进。目前无法独立证实这些报道。 以色列军方发言人纳达夫·肖沙尼中校表示,“媒体关于以色列坦克据称向大马士革推进的报道是错误的。” 他说,以色列军队驻扎在缓冲区内是为了保护以色列。 以色列军方此前曾表示,军队将进入缓冲区“以及其他几个对其防御必要的地区”。 与此同时,以色列媒体报道称,空军正在有条不紊地摧毁叙利亚的军事资产,以确保无论谁统治该国,都必须重建这些资产。 《以色列最大日报《耶迪奥特·阿赫罗诺特报》的军事记者约西·耶胡舒亚写道,这些行动“一直在系统地摧毁逃亡暴君军队残余的一切”。 “数十个目标,包括各种类型的武器库,都受到了袭击,以防止它们落入敌对分子手中并对以色列构成威胁。” 他补充说,空军“目前享有完全的行动自由”。 埃及、约旦和沙特阿拉伯谴责以色列的入侵,指责其利用叙利亚的混乱局面并违反国际法。 土耳其——与阿萨德对立——也谴责了以色列的推进。土耳其外交部指责以色列在叙利亚和平与稳定的可能性出现之际“表现出占领者的思维”。 联合国发言人斯蒂芬·杜雅里克周一表示,以色列的入侵构成对1974年脱离接触协议的违反,并呼吁以色列和叙利亚都遵守该协议。 ___ Mroue 从贝鲁特报道,Lidman 从以色列特拉维夫报道。美联社记者Suzan Fraser 从土耳其安卡拉对此报道做出了贡献。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More